Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
By working with medical professionals, consultants and NHS eLearning for Health PAS has the first dedicated 12 module education programme live on the NHS Learning Hub
Rybelsus Lawsuit Update 2026 Update July 1, 2026: MDL About Rybelsus, Other GLP-1 Drugs Gains Plaintiffs As of July 1, 2026, there are 3,848 lawsuits in the GLP-1 MDL, an increase of about 85 from the previous months starting count
When additional therapy is required, NICE recommends considering a GLP-1 receptor agonist (such as Rybelsus) if the patient has a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity, or if BMI is lower but insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities
If you want nutritional support that is designed to pair with GLP-1 treatment, GLP-1 Daily Support may be a fit for the times when appetite is down and hydration is harder to maintain
It has not been approved by the FDA or by any other regulator
